Videos

Gepirone, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults, is expected to arrive in early 2024.

"His wing Scythes down another day, his motion Is that of the honed steel-edge, we hear The crashless fall of stalks of Time."

Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.

Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.

What do autumn leaves signify?

"The sounds of the world at this late hour sadden you, but then enters the rain, hastening down, the rain that wants to touch everything and almost does."

Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!

Don't miss updates on schizophrenia at our conference, beginning at 3:10PM EST!

Experts in psychiatry review adverse effects of zuranolone, a γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.

Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.

How frequently is joy discussed in psychiatry?

Our Editor in Chief explains why you should attend our conference!

"My hands grown tired, my head weighed down with dreams..."

Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.

Experts in psychiatry comment on the use of GABAa receptor modulators in the treatment of major depressive disorder (MDD), highlighting zuranolone.

Share your experiences of awe with us!

"Oh for a stronger magic, that I could wave my arms and reach deep inside my white coat pocket, the mass vanished..."

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC; review the mechanism of action of newer therapies in MDD treatment.

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC, discuss provider and patient communication about the time to onset of action of major depressive disorder (MDD) treatments and when the patient can expect to see a difference.

Celebrating 3 years of Psychiatry & Society!

"And when they bombed other people’s houses, we protested but not enough, we opposed them but not enough..."

Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).

Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).

What's the psychiatry dress code?

"What luck—an open bookstore up ahead..."

Awe & astonishment: what benefits can they bring?

Medications for mental health and obesity: heavily stigmatized.

"Tornado or torbellino or something else, I ask her about the valley’s strange wind. And she laughs, says that she was calling to ask me the same thing."

New positive data for novel ADHD treatment.

In acute disasters, we see the best of people.